Rewriting the playbook: strategic responses to the inflation reduction act in the United States pharmaceutical industry

The passage of the Inflation Reduction Act (IRA) of 2022 (H.R. 5376) marks a significant shift in U.S. pharmaceutical policy by granting Medicare the authority to negotiate drug prices for high-cost drugs under Medicare Parts B and D (Seshamani, 2023). According to the Congressional Budget Office (CBO), the IRA is expected to save the U.S. Treasury over $100 billion by 2031 (Rome et al., 2023). While the savings are considerable, the implications for the pharmaceutical industry are wide ranging and historic. U.S. development costs can exceed $1.5 billion per new molecular entity (Wouters et al., 2020), and 90% of drugs fail to reach the market (Hay et al., 2014). The IRA creates a novel constraint for a free-market sector reliant on market-based pricing and governed by high investment barriers and high failure rates. External limitations on revenue realization, such as pricing constraints that may take effect before traditional exclusivity or patent milestones now enshrined in the IRA, directly impact future investment calculus and clinical development decisions. These new realities make this work a timely and consequential case study for industry, policymakers, and patients alike.This dissertation examines how pharmaceutical firms are responding to this statutory inflection point. Through a multi-phase qualitative study, I explore the strategic adaptations emerging in response to the IRA. Study 1 comprises of 20 semi-structured interviews with executives across pricing, portfolio strategy, medical affairs, evidence generation, government affairs, and others. Using the Gioia methodology (Gioia et.al., 2013), the data were coded, thematically organized, and synthesized into a grounded framework including seven aggregate dimensions. Study 2 triangulates these dimensions with public company disclosures, including 10-K filings, quarterly earnings calls, press releases, and CMS negotiation data, to evaluate how internal strategic intent corresponds with observable external signaling and lifecycle positioning. Findings from Study 1 suggest that the IRA is not just reshaping pricing; it is changing how the pharmaceutical industry behaves. Executives describe real time changes to launch sequencing, access strategy, evidence development, and organizational governance. Firms are building internal IRA playbooks and calibration of R&D priorities. Interviewees also cautioned about unintended consequences for Medicare beneficiaries. Negotiated drugs and patients seeking previously covered therapies may face step therapy, formulary exclusion, or other PBM-imposed access barriers, effectively limiting access despite lower prices. Study 2 introduces a structured timing overlay comparing CMS Maximum Fair Price (MFP) effectuation dates with FDA exclusivity and patent milestones. This analysis demonstrates that in a substantial portion of the first two negotiation cycles, Medicare price effectuation precedes traditional loss-of-exclusivity (LOE) benchmarks. The presence of this second statutory pricing clock, operating independently of patent protection, offers empirical context for executive concerns regarding compressed revenue windows, altered portfolio sequencing, and adjusted investment decisions. Beyond identifying adaptive dimensions, this study translates those findings into a structured set of competitive actions firms can deploy in response to legislated pricing constraints. All together the seven aggregate dimensions surfaced in this framework and the LOE-MFP overlay show how firms are adapting to the IRA and based on both studies why those adaptations are emerging. These competitive actions provide a practical roadmap linking internal organizational adaptation to external policy threats, strengthening the strategic management orientation of the work. This research provides timely insight into how drugmakers are adapting to a legislatively mandated pricing paradigm and as such is relevant to pharmaceutical executives in pricing, market access, R&D, strategy, government affairs, investor relations, as well as to policymakers at CMS and Congressional staff responsible for IRA oversight and reform. Trade organizations such as PhRMA and BIO have raised concerns about innovation disincentives; this study offers empirically grounded findings to inform that debate by offering context and insight into how U.S. firms are adapting to the IRA.